1.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CCCGHS-NCI-T98-0085, NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
|
|
2.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: A/100/0402, NCT00477906
|
|
3.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 111482, NCT00796445
|
|
4.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-RUH-NBH-0428-0401, RUH-NBH-0428-0401, NCI-5636, NCT00045383, 5636
|
|
5.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: over 18
Sponsor: Other
Protocol IDs: ERLANGEN-ONTAK, EU-20246, NCT00056134
|
|
6.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: ERLANGEN-DERMA-ER-DC-06, EU-20317, NCT00074230
|
|
7.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 to 90
Sponsor: Other
Protocol IDs: SuMo-Sec-01, PEI 0899/01, IRB 07/03, NCT00108875
|
|
8.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 80
Sponsor: Other
Protocol IDs: RNA-Mel-03, NCT00204516
|
|
9.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: MCC-13649, LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508
|
|
10.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: pepDCIL2- HMO-CTIL, NCT00279058
|
|
11.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 21 to 75
Sponsor: Other
Protocol IDs: Baylor IRB #006-025-01, 0000, NCT00313235
|
|
12.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: LUC 05-003, NCT00365937
|
|
13.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MM0413, NCT00197912
|
|
14.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 07-0652, NCT00683670
|
|
15.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2003-2917, KWF 2003-2917, NCT00243529
|
|
16.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI
Protocol IDs: DFCI-03123, NCT00085397
|
|
17.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2004-0502, NCT00254397
|
|
18.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0069, 7676, NCI-7676, NCI-P6703, NCT00304057
|
|
19.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 16
Sponsor: Other
Protocol IDs: HOAG-HCC-06-03, NCT00436930
|
|
20.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 15232B, NCT00515528
|
|
21.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2002-013, CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND, NCT00518206
|
|
22.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0056, 08-C-0056, NCI-P07193, NCT00612222
|
|
23.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0055, 08-C-0055, NCI-P07192, NCT00610311
|
|
24.
|
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: CD-2007-01, NCT00610389
|
|
25.
|
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0155, 08-C-0155, NCI-P07215, NCT00704938
|
